AveXis Inc. (AVXS) Stock Price Down 4.6%
AveXis Inc. (NASDAQ:AVXS) fell 4.6% during trading on Wednesday . The company traded as low as $42.46 and last traded at $42.71, with a volume of 380,618 shares. The stock had previously closed at $44.76.
A number of research firms recently commented on AVXS. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a report on Friday, June 24th. Chardan Capital reiterated a “buy” rating and set a $60.00 price target on shares of AveXis in a research report on Friday, August 12th. Jefferies Group lifted their price target on AveXis from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Monday. Finally, Wells Fargo & Co. assumed coverage on AveXis in a research report on Friday, July 15th. They set a “market perform” rating for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. AveXis presently has an average rating of “Buy” and an average price target of $47.00.
The firm’s market capitalization is $1.02 billion. The company’s 50 day moving average price is $37.48 and its 200-day moving average price is $34.03.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/avexis-inc-avxs-stock-price-down-4-6.html
AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.09. On average, equities analysts anticipate that AveXis Inc. will post ($3.30) EPS for the current fiscal year.
In other news, insider Paul B. Manning sold 289,855 shares of the firm’s stock in a transaction that occurred on Tuesday, September 13th. The stock was sold at an average price of $34.50, for a total value of $9,999,997.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Several hedge funds have recently bought and sold shares of AVXS. Foresite Capital Management III LLC acquired a new stake in AveXis during the first quarter valued at approximately $4,582,000. TIAA CREF Investment Management LLC acquired a new stake in AveXis during the first quarter valued at approximately $253,000. BlackRock Inc. acquired a new stake in AveXis during the first quarter valued at approximately $563,000. BlackRock Group LTD acquired a new stake in AveXis during the first quarter valued at approximately $2,223,000. Finally, BlackRock Fund Advisors acquired a new stake in AveXis during the first quarter valued at approximately $3,245,000. 54.46% of the stock is owned by institutional investors and hedge funds.
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.